Last $0.70 USD
Change Today +0.02 / 2.94%
Volume 75.2K
RGDX On Other Exchanges
As of 8:10 PM 10/30/14 All times are local (Market data is delayed by at least 15 minutes).

response genetics inc (RGDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/5/13 - $2.22
52 Week Low
10/7/14 - $0.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RESPONSE GENETICS INC (RGDX)

Related News

No related news articles were found.

response genetics inc (RGDX) Related Businessweek News

No Related Businessweek News Found

response genetics inc (RGDX) Details

Response Genetics, Inc., a life science company, is engaged in the research, development, marketing, and sale of pharmacogenomic tests for use in the treatment of cancer primarily in the United States, Asia, and Europe. It develops genetic tests that measure predictive factors for therapy response in tumor tissue samples. The company offers tests for non-small cell lung cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, and breast cancer patients’ tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, and ResponseDX: and Tissue of Origin test suites. It also provides HER2 mutation detection, cKIT mutation detection, MET gene amplification, and UGT1A1 SNP tests, including ROS1 FISH, ROS1 RT-PCR, c-MET, HER2 FISH, and VEGFR2. In addition, the company focuses on the development of various diagnostic tests for predicting therapy response and determining the diagnosis and prognosis of solid tumors in cancer patients. It serves community based oncologists, pathologists, physician offices, and hospitals, as well as pharmaceutical companies and cancer care centers through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

109 Employees
Last Reported Date: 03/31/14
Founded in 1999

response genetics inc (RGDX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $296.7K
Vice President of Research & Development
Total Annual Compensation: $333.5K
Compensation as of Fiscal Year 2013.

response genetics inc (RGDX) Key Developments

Response Genetics, Inc. Launches New and Innovative Non-Small Cell Lung Cancer Profile

Response Genetics Inc. announced it has launched a new and innovative Non-Small Cell Lung Cancer Profile that merges rapid turnaround on National Comprehensive Cancer Network (NCCN) guideline markers with next-generation sequencing (NGS). This new reflex, or sequential, testing program offers oncologists and pathologists a cost-effective way to utilize comprehensive cancer testing, including NGS, as a reflex-testing option for those patients who test negative for EGFR, ALK and ROS1, the biomarkers recommended by the NCCN.

Response Genetics, Inc. to Serve as the Molecular Screening Center for ALCHEMIST

Response Genetics Inc. announced that it has been awarded a multi-million dollar research subcontract to support the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST). ALCHEMIST consists of 3 integrated precision medicine trials that are being implemented through the National Clinical Trials Network (NCTN) of the National Cancer Institute (NCI) - a screening trial and two associated treatment trials. The research subcontract was awarded by Leidos Biomedical Research Inc., the operations and technical support contractor for the Frederick National Laboratory for Cancer Research, which is sponsored by NCI. ALCHEMIST will involve screening thousands of patients with resected early-stage lung cancer over a 5 to 6 year period in order to identify those patients with two specific gene changes: EGFR gene mutations and ALK gene rearrangement. Other goals of ALCHEMIST include defining biologic and molecular progression of early-stage lung cancer, evaluating two promising therapies in the adjuvant setting, and providing a public resource in which the genomic characterization of patients' tumors is tied to detailed clinical annotation, epidemiology data, and long-term outcome data.

Response Genetics, Inc Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Response Genetics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. Total revenue for the second quarter ended June 30, 2014 was $4.3 million compared to $3.9 million for the quarter ended March 31, 2014 and $5.3 million for the quarter ended June 30, 2013. The Company's net loss for the quarter ended June 30, 2014 was $3.1 million, or $0.08 per share, compared to a net loss of $3.5 million, or $0.09 per share, for the quarter ended March 31, 2014 and $1.3 million, or $0.04 per share, for the quarter ended June 30, 2013. Operating loss was $3,107,506 against $1,272,766 a year ago. For the six months, net revenue was $8,176,169, operating loss was $6,585,375 and net loss was $6,643,411 or $0.17 per basic and diluted share against net revenue of $10,938,105, operating loss of $2,056,897 and net loss of $2,121,458 or $0.06 per basic and diluted share for the same period a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGDX:US $0.70 USD +0.02

RGDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $26.99 USD +0.61
Genomic Health Inc $36.07 USD +1.23
NeoGenomics Inc $5.48 USD +0.15
Rosetta Genomics Ltd $3.10 USD +0.07
Veracyte Inc $7.96 USD +0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation RGDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESPONSE GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at